专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022248361A1 PHARMACEUTICAL COMPOSITION COMPRISING A CENTELLA ASIATICA EXTRACT 审中-公开
公开(公告)号：WO2022248361A1
公开(公告)日：2022-12-01
申请号：PCT/EP2022/063761
申请日：2022-05-20
申请人： ALMIRALL, S.A.
发明人： ILLERA FONTANET, Miquel , BOU ESPIGARES, Silvia , DEL BARRIO FRANCO, Pedro Antonio , ORTIZ FERRÓN, Francisco Javier , HUGHES, Melanie Jane , MACNAUGHTON, Katherine Jane , MEARS, John James
IPC分类号： A61K36/23 , A61P17/02 , A61K9/00 , A61K9/06 , A61K9/08 , A61K47/02 , A61K47/10
摘要： The present invention relates to a topical application which comprises Centella Asiatica extract (ECA). The composition can be used for the treatment of wounds.

2. 发明申请

WO2020053218A1 TREATMENT OF PSORIASIS 审中-公开
公开(公告)号：WO2020053218A1
公开(公告)日：2020-03-19
申请号：PCT/EP2019/074122
申请日：2019-09-10
申请人： ALMIRALL, S.A.
发明人： DIAZ GALLO, Maria Cristina , KAOUKHOV, Alexandre , SANZ SANTESTEBAN, Maria Teresa
IPC分类号： A61K31/225 , A61P17/06
摘要： The present invention relates to a method of treating psoriasis in a human patient, wherein the method comprises orally administering to the human patient a pharmaceutical dose form comprising dimethyl fumarate, and wherein the total amount of dimethyl fumarate administered per day is from 420 to 460 mg.

3. 发明申请

WO2019233722A1 PHARMACEUTICAL COMPOSITION COMPRISING TACROLIMUS 审中-公开
公开(公告)号：WO2019233722A1
公开(公告)日：2019-12-12
申请号：PCT/EP2019/062533
申请日：2019-05-15
申请人： ALMIRALL, S.A.
发明人： HERBIG, Michael Edgar , EVERS, Dirk-Heinrich , KÖLLMER, Melanie , FIELHAUER, Sabine , HAHN, Stefanie
IPC分类号： A61K9/00 , A61K47/06 , A61K47/14 , A61K9/107 , A61K31/436
摘要： The present invention relates to a pharmaceutical composition which is an oil-in- water emulsion comprising oil-phase droplets dispersed in an aqueous phase, wherein at least a proportion of the oil-phase droplets contain: (i) a macrolide compound which is tacrolimus, or a pharmaceutically acceptable salt or solvate thereof; (ii) a solvent in which the macrolide compound is soluble; and (iii) an antisolvent in which the macrolide compound is not soluble; wherein the oil-in-water emulsion further comprises (a) a first emulsifier and a second emulsifier, wherein the first emulsifier is more hydrophilic than the second emulsifier, or (b) a polymeric emulsifier and a non-polymeric emulsifier, and wherein the oil-in-water emulsion comprises water in an amount of from 30.0 to 75.0 wt% based on the total weight of the pharmaceutical composition.

4. 发明申请

WO2016198663A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS 审中-公开
标题翻译：作为JAK抑制剂的2-（吡唑并吡啶-3-基）吡啶衍生物
公开(公告)号：WO2016198663A1
公开(公告)日：2016-12-15
申请号：PCT/EP2016/063391
申请日：2016-06-10
申请人： ALMIRALL, S.A.
发明人： ESTEVE TRIAS, Cristina , TALTAVULL MOLL, Joan , GONZALEZ RODRIGUEZ, Jacob , VIDAL JUAN, Bernat
IPC分类号： A61K31/506 , A61K31/5377 , A61P3/00 , A61P5/00 , A61P9/00 , A61P11/00 , A61P17/00 , A61P25/00 , A61P31/12 , A61P35/00 , A61P37/00 , C07D471/04
CPC分类号： C07D471/04 , C07D239/24
摘要： New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
摘要翻译：公开了新的2-（吡唑并吡啶-3-基）嘧啶衍生物; 以及其制备方法，包含它们的药物组合物及其在治疗中作为Janus Kinases（JAK）抑制剂的用途。

5. 发明申请

WO2016170009A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS 审中-公开
标题翻译：氨基取代的杂环衍生物作为钠通道抑制剂
公开(公告)号：WO2016170009A1
公开(公告)日：2016-10-27
申请号：PCT/EP2016/058802
申请日：2016-04-20
申请人： ALMIRALL, S.A.
发明人： DUFFY, James , CHAMBERS, Mark Stuart , RAE, Alastair , OSBORNE, James , LEMASSON, Isabelle Anne , GOLDSMITH, Michael Daniel , SHARPE, Andrew , FONQUERNA POU, Silvia
IPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D231/38 , C07D401/04 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/12 , C07D249/14 , A61K31/4155 , A61P25/02 , A61P11/14 , A61P25/08 , A61P25/18 , A61P17/04
CPC分类号： C07D401/12 , A61P25/02 , C07D231/38 , C07D249/06 , C07D249/14 , C07D401/04 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/14
摘要： The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
摘要翻译：本发明涉及式（I）的新型氨基吲唑基衍生物化合物，所述化合物在治疗由电压门控钠通道调节特别是Nav1.7.7介导的疾病中的用途以及含有所述衍生物的组合物。

6. 发明申请

WO2015091531A1 IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS 审中-公开
标题翻译：作为JAK抑制剂的咪唑并吡啶-2-YL衍生物
公开(公告)号：WO2015091531A1
公开(公告)日：2015-06-25
申请号：PCT/EP2014/078037
申请日：2014-12-16
申请人： ALMIRALL, S.A.
发明人： BACH TAÑA, Jordi , PEREZ CRESPO, Daniel , LLERA SOLDEVILA, Oriol , ESTEVE TRIAS, Cristina , TABOADA MARTINEZ, Lorena
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00 , A61P37/00 , A61P29/00
CPC分类号： C07D471/04
摘要： New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.
摘要翻译：公开了新的咪唑并吡啶-2-基衍生物; 以及它们的制备方法，包含它们的药物组合物及其作为Janus Kinases（JAK）抑制剂用于治疗骨髓增生性疾病，白血病，淋巴恶性肿瘤和实体瘤的用途; 骨髓和器官移植排斥反应; 免疫介导的疾病和炎性疾病。

7. 发明申请

WO2015011244A1 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES 审中-公开
标题翻译：具有两种MUSCARINIC受体拮抗剂的2-氨基-1-羟基乙基-8-羟基喹啉-2（1H） - 酮衍生物和2种ADRENERGIC受体激动剂活性的体积
公开(公告)号：WO2015011244A1
公开(公告)日：2015-01-29
申请号：PCT/EP2014/065965
申请日：2014-07-24
申请人： ALMIRALL, S.A.
发明人： JULIA JANE, Montserrat , CARRERA CARRERA, Francesc , PRAT QUIÑONES, Maria , PUIG DURAN, Carlos , PAJUELO LORENZO, Francesca , PEREZ ANDRES, Juan Antonio
IPC分类号： A61K45/06 , A61K9/00 , A61K9/14 , A61K31/4725 , C07D409/14 , C07D275/06 , C07C57/15 , A61P11/00 , A61P11/06
CPC分类号： A61K31/4709 , A61K9/0075 , A61K9/008 , A61K31/4725 , A61K45/06 , C07B2200/13 , C07C57/15 , C07D275/06 , C07D409/14 , C07D417/14 , A61K2300/00
摘要： The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin- 2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
摘要翻译：本发明涉及（i）8-羟基喹啉-2（1H） - 酮衍生物和（ii）二羧酸或硫酰亚胺或其药学上可接受的溶剂合物的结晶加成盐。

8. 发明申请

WO2014131851A1 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES 审中-公开
标题翻译： 2-氨基-1-羟基乙基-8-羟基喹啉-2（1H） - 酮衍生物，具有二抗和二抗ADRENERGIC受体激动剂和M3 MUSCARINIC受体拮抗剂活性
公开(公告)号：WO2014131851A1
公开(公告)日：2014-09-04
申请号：PCT/EP2014/053871
申请日：2014-02-27
申请人： ALMIRALL, S.A.
发明人： APARICI VIRGILI, Monica , CALBET MURTRO, Marta , MIRALPEIX GUELL, Montserrat , GAVALDA MONEDERO, Amadeu , PUIG DURAN, Carlos
IPC分类号： A61K31/4709 , C07D409/14 , A61P11/00
CPC分类号： C07D409/14 , A61K9/0073 , A61K9/0075 , A61K31/4709 , A61K45/06 , C07B2200/13 , C07C59/255 , C07C309/05 , C07D275/06 , A61K2300/00
摘要： The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
摘要翻译：本发明涉及（i）8-羟基喹啉-2（1H） - 酮衍生物和（ii）羟基羧酸，磺酸或硫酰亚胺或其药学上可接受的溶剂合物的结晶加成盐。

9. 发明申请

WO2013107640A1 INHALATION DEVICE FOR POWDERED DRUGS 审中-公开
标题翻译：用于粉剂的吸入装置
公开(公告)号：WO2013107640A1
公开(公告)日：2013-07-25
申请号：PCT/EP2013/000126
申请日：2013-01-17
申请人： ALMIRALL, S.A.
发明人： HERDER, Martin , LUDANEK, Gerhard , METT, Ingo , SCHMIDT, Joachim
IPC分类号： A61M15/00
CPC分类号： A61M15/0066 , A61M15/0016 , A61M15/0026 , A61M15/0065 , A61M15/0073 , A61M15/0081 , A61M15/0091 , A61M15/0095 , A61M15/0096 , A61M2202/064 , A61M2205/584 , A61M2206/16 , F04C2270/0421
摘要： The invention relates to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient, said activating device being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when pressed by the patient. Said dosage key (5) while being pressed is only temporarily engaged with said transportation mechanism such that a metering cycle while be completed and the transportation mechanism and/or the metering means will be reset even if said dosage key (5) will be held in depressed condition.
摘要翻译：本发明涉及一种由吸入引起的气流由患者接收的粉末药物的吸入装置，其包括至少一个粉末储存器，用于从贮存器反复计量粉末剂量的计量装置，用于移动所述计量从填充位置的装置，用于将粉末剂量接收到用于将所述粉末剂量释放到粉末通道中的排空位置，用于由患者手动操作的至少一个致动装置，所述致动装置可操作地连接到所述运输机构，使得在操作时正在计量单一粉剂量，所述活化装置包括当由患者按压时作用在所述运输机构上的剂量密钥（5）。所述剂量键（5）在被按压时仅暂时与所述运送机构接合，使得即使所述剂量密钥（5）将被保持在中，也可以完成计量循环，并且运送机构和/或计量装置将被重置沮丧的状况。

10. 发明申请

WO2013068554A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES 审中-公开
标题翻译：具有BETA 2 ADRENERGIC AGONIST和M3 MUSCARINIC ANTAGONIST活动的新CYCLOHEXYLAMINE衍生物
公开(公告)号：WO2013068554A1
公开(公告)日：2013-05-16
申请号：PCT/EP2012/072311
申请日：2012-11-09
申请人： ALMIRALL, S.A.
发明人： AIGUADE BOSCH, Jose , GUAL ROIG, Silvia , PRAT QUINONES, Maria , PUIG DURAN, Carlos
IPC分类号： C07D403/12 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/4709 , A61P11/00
CPC分类号： A61K31/4184 , A61K31/428 , A61K31/4709 , A61K31/5377 , A61K45/06 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
摘要翻译：本发明涉及具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物，含有它们的药物组合物，其制备方法及其在呼吸治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式